TWI777325B - β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途 - Google Patents
β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途 Download PDFInfo
- Publication number
- TWI777325B TWI777325B TW109143679A TW109143679A TWI777325B TW I777325 B TWI777325 B TW I777325B TW 109143679 A TW109143679 A TW 109143679A TW 109143679 A TW109143679 A TW 109143679A TW I777325 B TWI777325 B TW I777325B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- formula
- kinase
- pharmaceutical composition
- tert
- Prior art date
Links
- 150000001576 beta-amino acids Chemical class 0.000 title claims abstract description 55
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 39
- 229940043355 kinase inhibitor Drugs 0.000 title claims description 21
- 239000003757 phosphotransferase inhibitor Substances 0.000 title claims description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 190
- 239000000203 mixture Substances 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 62
- 230000003287 optical effect Effects 0.000 claims abstract description 40
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims abstract description 22
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims abstract description 22
- 229940126657 Compound 17 Drugs 0.000 claims abstract description 22
- 229940126142 compound 16 Drugs 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 230000004410 intraocular pressure Effects 0.000 claims description 94
- 229940125810 compound 20 Drugs 0.000 claims description 68
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 68
- 229940012356 eye drops Drugs 0.000 claims description 41
- 206010030043 Ocular hypertension Diseases 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 33
- 208000010412 Glaucoma Diseases 0.000 claims description 28
- 102000001253 Protein Kinase Human genes 0.000 claims description 28
- 108060006633 protein kinase Proteins 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 26
- 108091000080 Phosphotransferase Proteins 0.000 claims description 25
- 230000005764 inhibitory process Effects 0.000 claims description 25
- 102000020233 phosphotransferase Human genes 0.000 claims description 25
- 101710109271 Mitogen-activated protein kinase 19 Proteins 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 108010067385 Myosin Light Chains Proteins 0.000 claims description 14
- 102000016349 Myosin Light Chains Human genes 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 9
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 206010074026 Exfoliation glaucoma Diseases 0.000 claims description 8
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 8
- 229940125904 compound 1 Drugs 0.000 claims description 8
- 229940125758 compound 15 Drugs 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 8
- 230000002685 pulmonary effect Effects 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 7
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 7
- 229940126086 compound 21 Drugs 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 7
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 7
- 208000001344 Macular Edema Diseases 0.000 claims description 6
- 206010025415 Macular oedema Diseases 0.000 claims description 6
- 239000003885 eye ointment Substances 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 201000010230 macular retinal edema Diseases 0.000 claims description 6
- 210000001328 optic nerve Anatomy 0.000 claims description 6
- 208000004683 Corneal Endothelial Cell Loss Diseases 0.000 claims description 5
- 206010014561 Emphysema Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 claims description 5
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 claims description 5
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 4
- 101710088411 Rho-associated protein kinase 1 Proteins 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 3
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 229940100655 ophthalmic gel Drugs 0.000 claims 2
- 229940069265 ophthalmic ointment Drugs 0.000 claims 2
- 150000002148 esters Chemical class 0.000 abstract description 31
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
- -1 coatings Substances 0.000 description 55
- 210000001508 eye Anatomy 0.000 description 53
- 238000005160 1H NMR spectroscopy Methods 0.000 description 48
- 238000012360 testing method Methods 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 239000003889 eye drop Substances 0.000 description 39
- 241000283973 Oryctolagus cuniculus Species 0.000 description 38
- 239000000243 solution Substances 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 35
- 238000003786 synthesis reaction Methods 0.000 description 35
- 235000019439 ethyl acetate Nutrition 0.000 description 34
- 230000000694 effects Effects 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 31
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 150000004677 hydrates Chemical class 0.000 description 20
- 239000000843 powder Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000002904 solvent Substances 0.000 description 19
- 230000002401 inhibitory effect Effects 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 230000001077 hypotensive effect Effects 0.000 description 17
- 208000001953 Hypotension Diseases 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 239000011324 bead Substances 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 239000007832 Na2SO4 Substances 0.000 description 15
- 208000021822 hypotensive Diseases 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 229910052938 sodium sulfate Inorganic materials 0.000 description 15
- 235000011152 sodium sulphate Nutrition 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000011555 rabbit model Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- 210000001742 aqueous humor Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 238000011587 new zealand white rabbit Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 230000004493 normal intraocular pressure Effects 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 206010015946 Eye irritation Diseases 0.000 description 7
- 231100000013 eye irritation Toxicity 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- MOHVPUYIGJGTCU-UHFFFAOYSA-N 3-amino-2-(4-fluorophenyl)-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC(=CC=C1C2=CNN=C2)NC(=O)C(CN)C3=CC=C(C=C3)F.Cl.Cl MOHVPUYIGJGTCU-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 210000005252 bulbus oculi Anatomy 0.000 description 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 6
- 210000000554 iris Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000003590 rho kinase inhibitor Substances 0.000 description 6
- 238000012353 t test Methods 0.000 description 6
- BWXMJCXGSQZRID-ZEECNFPPSA-N (2S)-3-amino-2-phenyl-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC=C(C=C1)[C@@H](CN)C(=O)NC2=CC=C(C=C2)C3=CNN=C3.Cl.Cl BWXMJCXGSQZRID-ZEECNFPPSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000009530 blood pressure measurement Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 210000001585 trabecular meshwork Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- BWXMJCXGSQZRID-RMRYJAPISA-N (2R)-3-amino-2-phenyl-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC=C(C=C1)[C@H](CN)C(=O)NC2=CC=C(C=C2)C3=CNN=C3.Cl.Cl BWXMJCXGSQZRID-RMRYJAPISA-N 0.000 description 4
- UCWTUEPSATUDAU-UHFFFAOYSA-N 2-benzyl-1-cyano-3-[4-(1H-pyrazol-4-yl)phenyl]guanidine hydrochloride Chemical compound C1=CC=C(C=C1)CN=C(NC#N)NC2=CC=C(C=C2)C3=CNN=C3.Cl UCWTUEPSATUDAU-UHFFFAOYSA-N 0.000 description 4
- RGVGZYXNPXVVAI-UHFFFAOYSA-N 3-amino-N-[2-fluoro-4-(1H-pyrazol-4-yl)phenyl]-2-phenylpropanamide dihydrochloride Chemical compound C1=CC=C(C=C1)C(CN)C(=O)NC2=C(C=C(C=C2)C3=CNN=C3)F.Cl.Cl RGVGZYXNPXVVAI-UHFFFAOYSA-N 0.000 description 4
- 206010018325 Congenital glaucomas Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 206010012565 Developmental glaucoma Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004240 ciliary body Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 239000012156 elution solvent Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 229950009210 netarsudil Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- FTPWWTUKCZPLGP-UHFFFAOYSA-N tert-butyl 4-[4-[[2-(4-hydroxyphenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)O FTPWWTUKCZPLGP-UHFFFAOYSA-N 0.000 description 4
- BSJFXAFLSWDUPK-UHFFFAOYSA-N tert-butyl pyrazole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC=N1 BSJFXAFLSWDUPK-UHFFFAOYSA-N 0.000 description 4
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- WNFAWYDESPZZIJ-KRWDZBQOSA-N (2R)-3-amino-2-phenyl-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)NC([C@@H](CN)C1=CC=CC=C1)=O WNFAWYDESPZZIJ-KRWDZBQOSA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- JPDQAZRWKFXEQL-UHFFFAOYSA-N 1-(2-amino-1-phenylethyl)-3-[4-(1H-pyrazol-4-yl)phenyl]thiourea dihydrochloride Chemical compound C1=CC=C(C=C1)C(CN)NC(=S)NC2=CC=C(C=C2)C3=CNN=C3.Cl.Cl JPDQAZRWKFXEQL-UHFFFAOYSA-N 0.000 description 3
- WMICNAGYHJNEBE-UHFFFAOYSA-N 3-amino-2-(4-formylphenyl)-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC(=CC=C1C=O)C(CN)C(=O)NC2=CC=C(C=C2)C3=CNN=C3.Cl.Cl WMICNAGYHJNEBE-UHFFFAOYSA-N 0.000 description 3
- QLFBTEMDACBFBQ-UHFFFAOYSA-N 3-amino-2-(4-hydroxyphenyl)-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC(=CC=C1C2=CNN=C2)NC(=O)C(CN)C3=CC=C(C=C3)O.Cl.Cl QLFBTEMDACBFBQ-UHFFFAOYSA-N 0.000 description 3
- DKKIPAJHEONGAU-UHFFFAOYSA-N 3-amino-2-phenyl-N-[4-(1H-pyrazol-4-yloxy)phenyl]propanamide dihydrochloride Chemical compound C1=CC=C(C=C1)C(CN)C(=O)NC2=CC=C(C=C2)OC3=CNN=C3.Cl.Cl DKKIPAJHEONGAU-UHFFFAOYSA-N 0.000 description 3
- OXSPWKORWXHXTC-UHFFFAOYSA-N 4-(3-tert-butylpyrazol-1-yl)-2-[2-(dimethylamino)ethoxy]aniline Chemical compound C(C)(C)(C)C1=NN(C=C1)C1=CC(=C(C=C1)N)OCCN(C)C OXSPWKORWXHXTC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101001005556 Homo sapiens Mitogen-activated protein kinase kinase kinase 19 Proteins 0.000 description 3
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 3
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 3
- 102100025217 Mitogen-activated protein kinase kinase kinase 19 Human genes 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- CYBBDHPJLUDBDA-UHFFFAOYSA-N [4-[3-amino-1-oxo-1-[4-(1H-pyrazol-4-yl)anilino]propan-2-yl]phenyl] 2,4-dimethylbenzoate dihydrochloride Chemical compound CC1=CC(=C(C=C1)C(=O)OC2=CC=C(C=C2)C(CN)C(=O)NC3=CC=C(C=C3)C4=CNN=C4)C.Cl.Cl CYBBDHPJLUDBDA-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- POLDHVZZCKZTMP-UHFFFAOYSA-N butyl pyrazole-1-carboxylate Chemical compound CCCCOC(=O)N1C=CC=N1 POLDHVZZCKZTMP-UHFFFAOYSA-N 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 229960000956 coumarin Drugs 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 201000004949 exfoliation syndrome Diseases 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 238000003359 percent control normalization Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IPISOFJLWYBCAV-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 IPISOFJLWYBCAV-UHFFFAOYSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- IOOWNWLVCOUUEX-WPRPVWTQSA-N 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid Chemical compound OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1 IOOWNWLVCOUUEX-WPRPVWTQSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ACVPAFMMIVZKMX-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-[4-[tri(propan-2-yl)silyloxymethyl]phenyl]propanoic acid Chemical compound CC(C)[Si](C(C)C)(C(C)C)OCC1=CC=C(C(CNC(=O)OC(C)(C)C)C(O)=O)C=C1 ACVPAFMMIVZKMX-UHFFFAOYSA-N 0.000 description 2
- PZRXRMWHLUUHFB-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)NCC(C(O)=O)C1=CC=CC=C1 PZRXRMWHLUUHFB-UHFFFAOYSA-N 0.000 description 2
- AILFMZTZCFTCJC-UHFFFAOYSA-N 3-amino-2-azido-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC(=CC=C1C2=CNN=C2)NC(=O)C(CN)N=[N+]=[N-].Cl.Cl AILFMZTZCFTCJC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- FRDIWEKEFIRISU-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)F Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)F FRDIWEKEFIRISU-UHFFFAOYSA-N 0.000 description 2
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000033051 Fuchs endothelial corneal dystrophy Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 231100000490 OECD 405 Acute Eye Irritation/Corrosion Toxicity 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 2
- 102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- KBJPUMPBZHPIAL-UHFFFAOYSA-N [4-[3-amino-1-oxo-1-[4-(1H-pyrazol-4-yl)anilino]propan-2-yl]phenyl]methyl 2,4-dimethylbenzoate dihydrochloride Chemical compound CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)C(CN)C(=O)NC3=CC=C(C=C3)C4=CNN=C4)C.Cl.Cl KBJPUMPBZHPIAL-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 2
- 229960002435 fasudil Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229940087419 nonoxynol-9 Drugs 0.000 description 2
- 229920004918 nonoxynol-9 Polymers 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
- ZEMGLMMDRJQQCM-UHFFFAOYSA-N tert-butyl 4-[4-[[2-[4-(2,4-dimethylbenzoyl)oxyphenyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)OC(C1=C(C=C(C=C1)C)C)=O ZEMGLMMDRJQQCM-UHFFFAOYSA-N 0.000 description 2
- XZOBVYFWCGMPLC-UHFFFAOYSA-N tert-butyl 4-[4-[[2-[4-[(2,4-dimethylbenzoyl)oxymethyl]phenyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)COC(C1=C(C=C(C=C1)C)C)=O XZOBVYFWCGMPLC-UHFFFAOYSA-N 0.000 description 2
- JONQFHXWXAHHHX-UHFFFAOYSA-N tert-butyl 4-hydroxypyrazole-1-carboxylate Chemical compound OC=1C=NN(C=1)C(=O)OC(C)(C)C JONQFHXWXAHHHX-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- WNFAWYDESPZZIJ-QGZVFWFLSA-N (2S)-3-amino-2-phenyl-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)NC([C@H](CN)C1=CC=CC=C1)=O WNFAWYDESPZZIJ-QGZVFWFLSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- NPLIJOZANQMZIS-UHFFFAOYSA-N 1,4-diazabicyclo[2.2.2]octane Chemical compound C1CN2CCN1CC2.C1CN2CCN1CC2 NPLIJOZANQMZIS-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- PLNDYSOYRCHXTE-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound FC1=CC=C(C=C1)[N+](=O)[O-].FC1=CC=C(C=C1)[N+](=O)[O-] PLNDYSOYRCHXTE-UHFFFAOYSA-N 0.000 description 1
- ITKCKDVPQJFCOV-UHFFFAOYSA-N 2,4-dimethylbenzoic acid dihydrochloride Chemical compound Cl.Cl.CC1=C(C(=O)O)C=CC(=C1)C ITKCKDVPQJFCOV-UHFFFAOYSA-N 0.000 description 1
- NXRGKFVQYZGDIY-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1.CC1=CC=CC(C)=N1 NXRGKFVQYZGDIY-UHFFFAOYSA-N 0.000 description 1
- PPSMYAUEJRADFE-HXUWFJFHSA-N 2-[(5r)-4-[2-[3-(6-methylpyridin-3-yl)oxyphenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound C1=NC(C)=CC=C1OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 PPSMYAUEJRADFE-HXUWFJFHSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- FWZBPBKAANKOJQ-UHFFFAOYSA-N 2-[4-(hydroxymethyl)phenyl]acetic acid Chemical compound OCC1=CC=C(CC(O)=O)C=C1 FWZBPBKAANKOJQ-UHFFFAOYSA-N 0.000 description 1
- IOZTZVNETUHASU-UHFFFAOYSA-N 2-[5-(1-tert-butylpyrazol-4-yl)-2-nitrophenoxy]-N,N-dimethylethanamine Chemical compound C(C)(C)(C)N1N=CC(=C1)C1=CC(=C(C=C1)[N+](=O)[O-])OCCN(C)C IOZTZVNETUHASU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- IVADUQQDYTXXQS-UHFFFAOYSA-N 2-azido-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCC(N=[N+]=[N-])C(O)=O IVADUQQDYTXXQS-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- CAEIJZYFTHNXFL-UHFFFAOYSA-N 3-amino-2-hydroxy-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC(=CC=C1C2=CNN=C2)NC(=O)C(CN)O.Cl.Cl CAEIJZYFTHNXFL-UHFFFAOYSA-N 0.000 description 1
- VOCLBFUXVGUKJW-UHFFFAOYSA-N 3-amino-2-phenoxy-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC=C(C=C1)OC(CN)C(=O)NC2=CC=C(C=C2)C3=CNN=C3.Cl.Cl VOCLBFUXVGUKJW-UHFFFAOYSA-N 0.000 description 1
- BNEAQGKBFFOOFD-UHFFFAOYSA-N 3-amino-2-phenyl-N-[4-(1H-pyrazol-4-yl)phenyl]propanethioamide dihydrochloride Chemical compound C1=CC=C(C=C1)C(CN)C(=S)NC2=CC=C(C=C2)C3=CNN=C3.Cl.Cl BNEAQGKBFFOOFD-UHFFFAOYSA-N 0.000 description 1
- OZJXPDHVPLVADG-UHFFFAOYSA-N 3-amino-2-phenylmethoxy-N-[4-(1H-pyrazol-4-yl)phenyl]propanamide dihydrochloride Chemical compound C1=CC=C(C=C1)COC(CN)C(=O)NC2=CC=C(C=C2)C3=CNN=C3.Cl.Cl OZJXPDHVPLVADG-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- WGFNCAIKIYRGTE-UHFFFAOYSA-N 4-(bromomethyl)isoindole-1,3-dione Chemical compound BrCC1=CC=CC2=C1C(=O)NC2=O WGFNCAIKIYRGTE-UHFFFAOYSA-N 0.000 description 1
- GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- CMDJNMACGABCKQ-XVSRHIFFSA-N 4-fluoro-5-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline;dihydrate;hydrochloride Chemical compound O.O.Cl.C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 CMDJNMACGABCKQ-XVSRHIFFSA-N 0.000 description 1
- KWLOIDOKWUESNM-UHFFFAOYSA-N 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1 KWLOIDOKWUESNM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- HLZCGKSILMYQME-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)CO[Si](C(C)C)(C(C)C)C(C)C Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)CO[Si](C(C)C)(C(C)C)C(C)C HLZCGKSILMYQME-UHFFFAOYSA-N 0.000 description 1
- YEFNNAQESQLYJJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)O[Si](C(C)C)(C(C)C)C(C)C Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)O[Si](C(C)C)(C(C)C)C(C)C YEFNNAQESQLYJJ-UHFFFAOYSA-N 0.000 description 1
- XXBHYJLNRNIHGN-UHFFFAOYSA-N CC(C)(C)C1(C=CC(C2=CNN=C2)=CC1OCCN(C)C)[N+]([O-])=O Chemical compound CC(C)(C)C1(C=CC(C2=CNN=C2)=CC1OCCN(C)C)[N+]([O-])=O XXBHYJLNRNIHGN-UHFFFAOYSA-N 0.000 description 1
- JBDBBVHLVOPPDE-UHFFFAOYSA-N CC1=C(C(=O)O)C=CC(=C1)C.CC1=C(C(=O)O)C=CC(=C1)C Chemical compound CC1=C(C(=O)O)C=CC(=C1)C.CC1=C(C(=O)O)C=CC(=C1)C JBDBBVHLVOPPDE-UHFFFAOYSA-N 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000584181 Homo sapiens Myosin light chain kinase family member 4 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 238000003720 Kinase-Glo Luminescent Kinase Assay Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100030782 Myosin light chain kinase family member 4 Human genes 0.000 description 1
- 101710109784 Myosin regulatory light chain 12B Proteins 0.000 description 1
- 101710092698 Myosin regulatory light chain 2 Proteins 0.000 description 1
- 101710112127 Myosin regulatory light chain 2, skeletal muscle isoform Proteins 0.000 description 1
- 101710105127 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Proteins 0.000 description 1
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 1
- WLGROPUPSQNREW-UHFFFAOYSA-N N-(2-aminoethyl)-N-[(4-fluorophenyl)methyl]-4-(1H-pyrazol-4-yl)benzamide dihydrochloride Chemical compound C1=CC(=CC=C1CN(CCN)C(=O)C2=CC=C(C=C2)C3=CNN=C3)F.Cl.Cl WLGROPUPSQNREW-UHFFFAOYSA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037508 Punctate keratitis Diseases 0.000 description 1
- 101150111584 RHOA gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZRFVNNCSPNLIJO-UHFFFAOYSA-N [Fe].[Rb] Chemical compound [Fe].[Rb] ZRFVNNCSPNLIJO-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000025194 apoptotic cell clearance Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 231100000269 corneal opacity Toxicity 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- QWASAGQCQSHFHZ-UHFFFAOYSA-N cyanamide Chemical compound NC#N.NC#N QWASAGQCQSHFHZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- LLDQUDYCTIKKFV-UHFFFAOYSA-N methyl 2-[4-(hydroxymethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=C(CO)C=C1 LLDQUDYCTIKKFV-UHFFFAOYSA-N 0.000 description 1
- ZVXBFYNEEWHDPI-UHFFFAOYSA-N methyl 3-(1,3-dioxoisoindol-2-yl)-2-[4-[tri(propan-2-yl)silyloxymethyl]phenyl]propanoate Chemical compound O=C1C2=CC=CC=C2C(=O)N1CC(C(=O)OC)C1=CC=C(CO[Si](C(C)C)(C(C)C)C(C)C)C=C1 ZVXBFYNEEWHDPI-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 201000002761 non-arteritic anterior ischemic optic neuropathy Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 201000006366 primary open angle glaucoma Diseases 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 201000003827 punctate epithelial keratoconjunctivitis Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- QSKQVZWVLOIIEV-NSHDSACASA-N ripasudil Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 QSKQVZWVLOIIEV-NSHDSACASA-N 0.000 description 1
- 229950007455 ripasudil Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- KVUXAFAVIYOFPO-UHFFFAOYSA-N tert-butyl 4-[3-fluoro-4-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylpropanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=C(C=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)F)C1=CC=CC=C1 KVUXAFAVIYOFPO-UHFFFAOYSA-N 0.000 description 1
- LIXKVNVRWKZWSC-UHFFFAOYSA-N tert-butyl 4-[4-(benzylcarbamothioylamino)phenyl]pyrazole-1-carboxylate Chemical compound C(C1=CC=CC=C1)NC(NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)=S LIXKVNVRWKZWSC-UHFFFAOYSA-N 0.000 description 1
- BOKFAAITLVLRBO-UHFFFAOYSA-N tert-butyl 4-[4-[(4-fluorophenyl)methyl-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]carbamoyl]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCCN(C(=O)C1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)CC1=CC=C(C=C1)F BOKFAAITLVLRBO-UHFFFAOYSA-N 0.000 description 1
- KETKYMBSHJVYJC-UHFFFAOYSA-N tert-butyl 4-[4-[[2-(4-formylphenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)C=O KETKYMBSHJVYJC-UHFFFAOYSA-N 0.000 description 1
- NYEHFAIBGCEXPW-UHFFFAOYSA-N tert-butyl 4-[4-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1-phenylethyl]carbamothioylamino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C1=CC=CC=C1)NC(NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)=S NYEHFAIBGCEXPW-UHFFFAOYSA-N 0.000 description 1
- RBJRFFQOXILZQH-UHFFFAOYSA-N tert-butyl 4-[4-[[2-[4-(hydroxymethyl)phenyl]-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=C(C=C1)CO RBJRFFQOXILZQH-UHFFFAOYSA-N 0.000 description 1
- KRRZNTDNLNMACR-UHFFFAOYSA-N tert-butyl 4-[4-[[2-azido-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound N(=[N+]=[N-])C(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)CNC(=O)OC(C)(C)C KRRZNTDNLNMACR-UHFFFAOYSA-N 0.000 description 1
- LOWVXQONMSJAJC-UHFFFAOYSA-N tert-butyl 4-[4-[[2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)O LOWVXQONMSJAJC-UHFFFAOYSA-N 0.000 description 1
- MSHOVRQDGJXDDJ-UHFFFAOYSA-N tert-butyl 4-[4-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(4-phenyltriazol-1-yl)propanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)N1N=NC(=C1)C1=CC=CC=C1 MSHOVRQDGJXDDJ-UHFFFAOYSA-N 0.000 description 1
- QRPDISAGVKLTSX-UHFFFAOYSA-N tert-butyl 4-[4-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenoxypropanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)OC1=CC=CC=C1 QRPDISAGVKLTSX-UHFFFAOYSA-N 0.000 description 1
- ZYQRMHKAFMCJFR-UHFFFAOYSA-N tert-butyl 4-[4-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylmethoxypropanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C1=CC=CC=C1)OC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)CNC(=O)OC(C)(C)C ZYQRMHKAFMCJFR-UHFFFAOYSA-N 0.000 description 1
- KHRPXUVAIBZONG-UHFFFAOYSA-N tert-butyl 4-[4-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylpropanethioyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)=S)C1=CC=CC=C1 KHRPXUVAIBZONG-UHFFFAOYSA-N 0.000 description 1
- HZWZGWCGPYMPND-UHFFFAOYSA-N tert-butyl 4-[4-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylpropanoyl]amino]phenoxy]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(OC=2C=NN(C=2)C(=O)OC(C)(C)C)C=C1)C1=CC=CC=C1 HZWZGWCGPYMPND-UHFFFAOYSA-N 0.000 description 1
- HCNKLZBAYTTYOD-UHFFFAOYSA-N tert-butyl 4-[4-[[3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylpropanoyl]amino]phenyl]pyrazole-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)NCC(C(=O)NC1=CC=C(C=C1)C=1C=NN(C=1)C(=O)OC(C)(C)C)C1=CC=CC=C1 HCNKLZBAYTTYOD-UHFFFAOYSA-N 0.000 description 1
- CLUUDOMFHPDBIR-UHFFFAOYSA-N tert-butyl n-(2-amino-2-phenylethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC(N)C1=CC=CC=C1 CLUUDOMFHPDBIR-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LHJCZOXMCGQVDQ-UHFFFAOYSA-N tri(propan-2-yl)silyl trifluoromethanesulfonate Chemical compound CC(C)[Si](C(C)C)(C(C)C)OS(=O)(=O)C(F)(F)F LHJCZOXMCGQVDQ-UHFFFAOYSA-N 0.000 description 1
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 150000003754 zirconium Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200188968A KR102758256B1 (ko) | 2019-12-31 | 2020-12-31 | β-아미노산 유도체, 키나아제 억제제 및 이를 함유하는 약학 조성물 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962955683P | 2019-12-31 | 2019-12-31 | |
| US62/955,683 | 2019-12-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202126628A TW202126628A (zh) | 2021-07-16 |
| TWI777325B true TWI777325B (zh) | 2022-09-11 |
Family
ID=74556625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109143679A TWI777325B (zh) | 2019-12-31 | 2020-12-10 | β-胺基酸衍生物、含其之激酶抑制劑與醫藥組成物以及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11608319B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3845276B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7531379B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN113121443B (cg-RX-API-DMAC10.html) |
| ES (1) | ES3015621T3 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI777325B (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230038697A (ko) * | 2020-07-14 | 2023-03-21 | 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 | Rock 억제제 및 이의 제조 방법과 용도 |
| WO2025143152A1 (ja) | 2023-12-27 | 2025-07-03 | 全薬工業株式会社 | チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120135984A1 (en) * | 2009-05-01 | 2012-05-31 | Delong Mitchell A | Dual-action inhbitors and methods of using same |
| WO2018094362A1 (en) * | 2016-11-21 | 2018-05-24 | Translational Drug Development, Llc | Heterocyclic compounds as kinase inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| CN101253152A (zh) * | 2005-09-02 | 2008-08-27 | 安斯泰来制药株式会社 | 作为rock抑制剂的酰胺衍生物 |
| US8504218B2 (en) | 2007-07-31 | 2013-08-06 | General Electric Company | Methods and systems for universal input output for vehicle control |
| JP2011507850A (ja) * | 2007-12-21 | 2011-03-10 | ザ スクリプス リサーチ インスティチュート | Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| KR101768235B1 (ko) | 2009-07-28 | 2017-08-14 | 오노 야꾸힝 고교 가부시키가이샤 | 이환식 화합물 및 이의 의약 용도 |
| KR102074020B1 (ko) | 2012-07-13 | 2020-02-05 | 산텐 세이야꾸 가부시키가이샤 | 술폰아미드 화합물의 조합 |
| EP2961746B1 (en) * | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AU2016264220A1 (en) | 2015-05-18 | 2018-01-04 | Translational Drug Development Llc | Heterocyclic compounds as kinase inhibitors |
| JP2019529359A (ja) * | 2016-08-19 | 2019-10-17 | アエリエ ファーマシューティカルズ インコーポレイテッド | ベータ−アミノ−イソキノリニルアミド化合物 |
| CN111050766A (zh) * | 2017-07-21 | 2020-04-21 | 卡德门企业有限公司 | Rho相关含卷曲螺旋蛋白激酶的抑制剂 |
| US20210087184A1 (en) * | 2018-03-14 | 2021-03-25 | Aerie Pharmaceuticals, Inc. | Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds |
-
2020
- 2020-12-10 CN CN202011454931.0A patent/CN113121443B/zh active Active
- 2020-12-10 JP JP2020204848A patent/JP7531379B2/ja active Active
- 2020-12-10 TW TW109143679A patent/TWI777325B/zh active
- 2020-12-10 EP EP20213242.9A patent/EP3845276B1/en active Active
- 2020-12-10 US US17/117,615 patent/US11608319B2/en active Active
- 2020-12-10 ES ES20213242T patent/ES3015621T3/es active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120135984A1 (en) * | 2009-05-01 | 2012-05-31 | Delong Mitchell A | Dual-action inhbitors and methods of using same |
| WO2018094362A1 (en) * | 2016-11-21 | 2018-05-24 | Translational Drug Development, Llc | Heterocyclic compounds as kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202126628A (zh) | 2021-07-16 |
| JP7531379B2 (ja) | 2024-08-09 |
| EP3845276B1 (en) | 2025-01-29 |
| CN113121443A (zh) | 2021-07-16 |
| US11608319B2 (en) | 2023-03-21 |
| CN113121443B (zh) | 2024-07-09 |
| EP3845276A1 (en) | 2021-07-07 |
| US20220363645A1 (en) | 2022-11-17 |
| JP2021113185A (ja) | 2021-08-05 |
| ES3015621T3 (en) | 2025-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7820670B2 (en) | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | |
| TWI839375B (zh) | 一氧化氮釋放第５型磷酸二酯酶抑制劑 | |
| JP2011518816A (ja) | Ｐｌｋインヒビター | |
| TR201802280T4 (tr) | İnsan protein tirosin fosfataz inhibitörleri ve bunların farmasötik kullanımları. | |
| PT1888548E (pt) | Derivado de quinolina para o tratamento de doenças da retina | |
| WO2012072033A1 (zh) | 取代的2，3-二氮杂萘酮化合物及其用途 | |
| KR20140145203A (ko) | 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체 | |
| BR112020019560A2 (pt) | Moduladores de calpaína e usos terapêuticos dos mesmos | |
| CN113121443B (zh) | β-氨基酸衍生物、含其之激酶抑制剂与医药组合物以及其用途 | |
| US20170065602A1 (en) | Compounds with trpv4 activity, compositions and associated methods thereof | |
| KR102758256B1 (ko) | β-아미노산 유도체, 키나아제 억제제 및 이를 함유하는 약학 조성물 | |
| JP2019522673A (ja) | Ｈｔｒａ１阻害剤としての新規なジフルオロケトアミド誘導体 | |
| EP3409659A1 (en) | Adamantane derivative and use thereof | |
| CN113228201B (zh) | 治疗青光眼的钙蛋白酶-2选择性抑制剂化合物 | |
| CN109641857A (zh) | 作为n-甲酰基肽受体调节剂的苯基脲衍生物 | |
| TW202233623A (zh) | 氮氧化物供與的pde-5及/或pde-6抑制劑化合物及其用途 | |
| CN100422161C (zh) | 羟基吗啉酮衍生物及其医药用途 | |
| US12503476B2 (en) | Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria | |
| KR20190138824A (ko) | 치환된 n-아릴에틸-2-아릴퀴놀린-4-카르복스아미드 및 그의 용도 | |
| WO2011140681A1 (zh) | 丙烯酰胺类化合物及其抑制细胞凋亡的用途 | |
| HK40120357A (en) | Nitric oxide releasing phosphodiesterase type 5 inhibitor | |
| WO2024168165A2 (en) | Telomerase inhibitor compounds | |
| HK40049475A (en) | Nitric oxide releasing phosphodiesterase type 5 inhibitor | |
| HK40049475B (en) | Nitric oxide releasing phosphodiesterase type 5 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD4A | Issue of patent certificate for granted invention patent |